Analyst Michael Matson from Needham maintained a Buy rating on Haemonetics (HAE – Research Report) and decreased the price target to $84.00 from $104.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Michael Matson has given his Buy rating due to a combination of factors including Haemonetics’s ability to surpass expectations in their fourth-quarter revenue and earnings per share (EPS). Despite the company’s guidance for fiscal year 2026 being slightly below consensus at the midpoint, the stable organic growth and improved margins indicate a positive outlook.
The company’s gross and operating margins have shown significant year-over-year improvement, which suggests operational efficiency and cost management. Although the EPS guidance was lower than consensus, it exceeded expectations when considering the impact of tariffs, which were not fully accounted for in consensus estimates. These factors collectively support the Buy rating, although the price target has been adjusted to $84 from $104.